India, Feb. 21 -- Lupin announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, for the inspection conducted from 27 January to 31 January 2025.
Published by HT Digital Content Services with permission from Pivotal Sources....